CD8A and COVID-19: According to the results of this study, we suggest that patients with severe COVID-19 or patients bearing the risk of developing severe COVID-19 may benefit from immunotherapy with autologous CD8+ T lymphocytes and/or cytokine up-regulating the number and function of CD8+ T lymphocytes.